High-mobility group (HMG) A1 proteins are gene regulatory factors whose overexpression is frequently observed in naturally occurring human cancers. The overexpression of transgenic HMGA1 proteins in cells results in neoplastic transformation and promotes progression to malignant cellular phenotypes. To understand the underlying molecular and biological events involved in these phenomena, we used oligonucleotide microarray analyses to generate an HMGA1a-induced expression profile for approximately 22 000 genes. This gene expression profile was generated using a well-characterized transgenic human MCF-7 mammary adenocarcinoma cell line in which overexpression of transgenic HMGA1 promotes a transition to a more malignant and metastatic phenotype. Microarray expression analyses, together with independent quantitative real-time reverse transcriptase polymerase chain reaction results, indicate that HMGA1a regulates genes involved in the Ras-extracellular signalrelated kinase (Ras/ERK) mitogenic signaling pathway, including KIT ligand and caveolins 1 and 2. We also found that many cholesterol biosynthesis genes were decreased in cells overexpressing HMGA1a. Cholesterol depletion, decreased caveolin, and increased KIT ligand expression, are all independently associated with the activation of Ras/ERK signaling. Upon further analysis, we found that sensitivity to epidermal growth factor activation of ERK phosphorylation was significantly higher, and that cholesterol was significantly depleted, in cells overexpressing HMGA1a. The cumulative evidence indicates that one likely mechanism by which the HMGA1a protein promotes malignant changes in cells is through increased sensitivity to the activation of the Ras/ERK signaling pathway.
Introduction
The mammalian high-mobility group (HMG) nonhistone chromatin proteins are composed of three protein families, HMGA (formerly called HMG-I/Y), HMG-B (formerly called HMG-1/2) and HMGN (formerly called HMG-14/17 (Bustin, 2001) ), which have structurally distinct DNA-binding domains (Thomas and Travers, 2001 ). The distinguishing feature of the HMGA proteins is the presence in each protein of three independent DNA-binding peptide motifs, called 'AT hooks', which preferentially bind to the minor groove of AT-rich regions of B-form DNA (Reeves and Nissen, 1990) . Members of the HMGA protein family are coded for by two different genes, HMGA1 and HMGA2, which are located on different chromosomes in humans (reviewed in Reeves, 2000) . The human HMGA1 gene codes for two major protein isoforms, HMGA1a (a.k.a, HMG-I) and HMGA1b (a.k.a, HMG-Y), which differ by 11 internal amino acids as a result of alternative messenger RNA splicing (Johnson et al., 1989; Friedmann et al., 1993) . HMGA1 proteins are architectural transcription factors that regulate the transcriptional activity of a large number of mammalian genes by inducing changes in chromatin structure and by controlling the formation of stereo-specific, multiprotein complexes called 'enhancesomes' on the promoter/ enhancer regions of genes (reviewed in Reeves and Beckerbauer, 2001; Reeves, 2001) . HMGA1 proteins are also among the most highly modified of all the mammalian nuclear proteins, and their complex patterns of secondary biochemical modifications have been demonstrated to modulate their in vivo biological activity and function (Banks et al., 2000; review in Reeves, 2001 ). Both the post-transcriptional biochemical modifications found on HMGA1 proteins in vivo and the transcriptional activity of the HMGA1 gene itself (Friedmann et al., 1993; Ogram and Reeves, 1995) are direct downstream targets of numerous signal transduction pathways making them highly responsive to various external environmental stimuli (review in Reeves, 2001) .
HMGA1 is a bona fide oncogene whose artificially induced overexpression causes both neoplastic transformation of nonmalignant cells (Wood et al., 2000a) and promotes the progression of tumor cells from a low grade of malignancy to a highly metastatic and aggressive phenotype . Importantly, constitutively high levels of HMGA1 proteins are also found in many different types of naturally occurring cancers, including those of the colon, prostate, thyroid, breast, pancreas, uterus, skin, intestine, brain, lung, and blood (Giancotti et al., 1989; Ram et al., 1993; Tamimi et al., 1993; Chiappetta et al., 1995; Fedele et al., 1996; Bandiera et al., 1998; Giannini et al., 1999; Abe et al., 2000; Rajeswari et al., 2001; Pierantoni et al., 2003, respectively) , while the expression levels in normal differentiated somatic tissues are usually extremely low and often nearly undetectable (Johnson et al., 1988 (Johnson et al., , 1989 Lundberg et al., 1989) . Indeed, HMGA1 overexpression is such a consistent and widespread feature of cancers that it has been suggested to be a diagnostic marker of neoplastic transformation with increasing cellular protein concentrations being associated with increasing degrees of malignancy and metastatic potential (reviewed in Tallini and Dal Cin, 1999; Reeves, 2000; Reeves and Beckerbauer, 2001) . Intriguingly, transcription of the HMGA1 gene is regulated by both c-Myc (Wood et al., 2000b) and AP-1 (Ogram and Reeves, 1995) oncogenic transcription factors, which are aberrantly expressed in a variety of tumors.
Together, the above results imply that the HMGA1 gene and its protein products are attractive targets for potential anticancer chemotherapy. Consistent with this suggestion is the observation that antisense inhibition of HMGA1 gene expression prevents neoplastic transformation of rat thyroid cells and partially reverses the malignant phenotype of both Burkitt's lymphoma (Wood et al., 2000b) and other highly malignant cancer cells . Antisense inhibition of HMGA1 expression also induces apoptosis in anaplastic human thyroid cancer cells but not in normal thyroid cells (Scala et al., 2000) . Furthermore, a mitosense-based antitumor drug (FK317) that chemically crosslinks HMGA1 proteins to the minor groove of DNA in vivo (Beckerbauer et al., 2000) is currently being evaluated in clinical trials as a potential new anticancer drug. Since increased HMGA1 protein expression is widespread in human cancers and has shown promise as a chemotherapeutic target, understanding the molecular mechanisms that underlie its oncogenic activity should have important clinical implications.
In this study, we investigated the effects that physiologically relevant overexpression of the HMGA1a isoform protein has on the transcription of endogenous genes in genetically engineered MCF-7 cells. In order to identify HMGA1a-regulated genes, we used a stable MCF-7 cell line (M/tet/HA-I) that exhibited constitutive expression of a transgenic HA-tagged HMGA1a protein, in the absence of tetracycline , and characterized the expression profile of over 22 000 endogenous human genes for a response to HMGA1a overexpression. Previous studies have demonstrated that when HMGA1a protein is overexpressed in these transgenic MCF-7 cells they acquire a much more malignant phenotype. These HMGA1a-overexpressing cells acquire the ability to grow in an anchorageindependent manner in soft agarose, form primary and metastatic tumors when injected into nude mice, and undergo morphological and biochemical changes characteristic of a transition from an epithelial to a mesenchymal phenotype . Aberrant expression of HMGA1-regulated genes, with functions related to malignant progression of breast cancer, has been suggested to promote these pathological phenotypic changes. For example, prior work from our laboratory revealed that genes coding for certain cell surface integrin proteins and intracellular proteins in integrin signaling pathways are upregulated in response to overexpression of the HMGA1b isoform protein in transgenic MCF-7 cells . Here, we report results from expression analyses using highdensity oligonucleotide microarrays, indicating that the HMGA1a isoform protein, like the HMGA1b protein, also regulates genes in MCF-7 cells associated with increased tumorigenic potential. In addition, we have identified the Ras-extracellular signal-related kinase (Ras/ERK) signaling pathway as one of the likely molecular mechanisms by which overexpression of HMGA1a proteins promotes malignant metastatic progression of mammary cell tumors. Importantly, the present results provide additional support to the notion that the HMGA1 gene and its encoded proteins are potential new chemotherapeutic targets for inhibiting the activation of the Ras/ERK pathway in cancer cells.
Results
RNA was extracted from well-characterized parental (control) MCF-7 cells and from 'HMGA1a-ON' transgenic MCF-7 cells that constitutively overexpress transgenic HMGA1a protein in the absence of tetracycline ) and used to synthesize biotinylated 'target' cRNAs. These 'target' cRNAs were then used as hybridization probes for screening highdensity oligonucleotide microarrays. The resulting hybridization signals on the microarrays allowed for a quantitative determination of the relative amount of transcriptional expression of individual genes in both the control and the 'ON' MCF-7 cells. The hybridization data also provided an unbiased assessment of whether or not the relative expression of a particular endogenous gene was decreased or increased in response to HMGA1a protein overexpression in cells. Target cRNAs were prepared in three independent isolations from both control and HMGA1a-overexpressing cell lines. For statistical purposes, three independent microarray analyses were performed in order to reduce the occurrence of both false-positive and false-negative gene classification (Lee et al., 2000) significantly. Generating three replicates also allowed for reliable analysis of genes whose expression exhibited a change of 71.5-fold or greater (Daoud et al., 2003) . The Affymetrix U133A oligonucleotide microarray chips used for these hybridization analyses contained probe sets for approximately 22 000 well-characterized human genes.
The analysis of the oligonucleotide microarrays using the Microarray Suite program (MAS, vers. 5.0; Affymetrix) provided a statistical means to determine the changes in the levels of expression of a given gene in an experimental sample. The outcome was based on comparison of the hybridization efficiency, or signal, of the target cRNA to its complementary sequence. This comparison took into account crosshybridization of the target cRNA of that gene to a mismatch sequence that is exactly the same as the complementary sequence with the exception of one base. For each gene on the array, there are 11 exact match complementary probes, each with a corresponding noncomplementary probe with one mismatch. The sequences of the complementary probes for any given gene were selected from distinct regions of that gene.
Comparative analyses were carried out with the MAS program using the levels of endogenous gene expression found in the parental MCF-7 cell line (control), which was not overexpressing HMGA1a protein, as the baseline. The genes whose expression in HMGA1a-overexpressing cells, relative to the control, was consistently regulated either upward or downward by more than twofold in each of the three independent replicate microarray hybridization experiments, are listed in Table 1 . A 36.8713.9-fold increase in HMGA1 gene expression was observed by microarray analysis in the HMGA1a-ON transgenic MCF-7 cells compared to the nontransgene-expressing parental (control) MCF-7 cells. As expected, in each of the three independent microarray data sets analysed, the substantial upregulation of HMGA1a seen in HMGA1a-ON transgenic MCF-7 cells represented the most significant fold change in gene expression levels observed among all of the 22 215 human genes represented on the arrays. In each experiment, this marked increase in HMGA1a expression levels in the HMGA1a-ON, versus control, cells was independently confirmed by reverse transcriptase polymerase chain reaction (PCR), Northern, and Western analyses prior to microarray analysis ( Figure 1 ). Of particular importance is the fact that the 36.8713.9-fold change in HMGA1 gene expression, observed here, is within the physiological range of overexpression observed previously in naturally occurring cancer tissues (from 5-to 200-fold) (Giancotti et al., 1987; Johnson et al., 1988; Ram et al., 1993; Giannini et al., 2000; Nam et al., 2003; reviewed in Bustin and Reeves, 1996; Tallini and Dal Cin, 1999) .
To further validate the microarray data, quantitative real-time reverse transcriptase PCR (Q-PCR) was used to characterize the differential expression of several of the genes in Table 1 , including the caveolin 1, caveolin 2, and Kit ligand (KITLG) genes (Figure 2 ), which play a role in Ras/ERK signaling. The overall trend in altered gene expression levels for caveolin 1 (À2.970.3), Microarray data were also characterized using Gen-MAPP (Gene Microarray Pathway Profiler; Gladstone Institutes), a program designed to view and analyse gene expression data in the context of biological pathways (Dahlquist, 2002; Doniger et al., 2003) . The criteria for increased and decreased gene expression levels using this program were set at X1.5 and pÀ1.5-fold change, respectively. Gene expression data were entered into GenMAPP as the average of three replicate data sets. This provided statistical confidence for using the 71.5-fold difference in expression levels as valid criteria (Daoud et al., 2003) . Analysis using the subdirectory 'Metabolic MAPPs' of the GenMAPP program revealed subtle decreases in the expression of a number of genes involved in cholesterol biosynthesis, including HMG-CoA reductase, mevalonate kinase, mevalonate pyrophosphate decarboxylase, 7-dehydrocholesterol reductase, and isopentenyl pyrophosphate isomerase ( Table 2) . As an independent confirmation of the prediction of these microarray and GenMAPP analyses, we also experimentally demonstrated (Figure 3) that the total cholesterol level was significantly lower (o45%) in HMGA1a-ON transgenic cells overexpressing HMGA1a (6.671.2 ng cholesterol/mg cellular protein) compared to untreated control cells not overexpressing HMGA1a (14.971.4 ng cholesterol/mg cellular protein). Additional GenMAPP analyses using the same criteria (71.5-fold change) revealed both subtle and significant changes in the expression of genes involved in Rasextracellular signal-regulated kinase (Ras/ERK) signal transduction (Figure 4 ). These included decreased expression of caveolin 1, caveolin 2, and PPAR-g, and increased expression of KITLG, its receptor, c-kit, and For RT-PCR, the addition of primers for the housekeeping gene hypoxanthine phosphoribosyl transferase (HPRT1) was used as a normalization control, the positive control reaction ( þ ) was carried out with pTRE-HA7C expression vector DNA as template, and the negative control (À) was carried out with no template. For Northern analysis, the 18S ribosomal RNA band from the ethidium-stained formaldehyde gel was used as a loading control. For Western analysis, the minor crossreactivity of crude anti-HMGA1 serum for histone H1 (H1) on the blots was used, along with Coomassie Blue staining of the proteins on SDS-polyacrylamide gels, used as a protein loading control reference standard To further validate these GenMAPP predictions, we performed experiments to determine whether there were detectable differences in the Ras/ERK pathway in the untreated 'control' and HMGA1a-ON cells by investigating the properties of the ERK protein, the last common downstream member of this signaling cascade (Figure 4 ). Since microarray analyses did not reveal a significant difference in the levels of ERK mRNA expression in control versus HMGA1a-overexpressing cells ( Figure 5 ; unpublished data), we assessed whether there might be detectable differences in the levels of phosphorylated ERK protein in these cells. For these experiments, we used Western blot analysis with a specific anti-phospho-ERK antibody to determine the sensitivity of control and HMGA1a-overexpressing cells to epidermal growth factor (EGF) exposure. As shown in Figure 5 , and consistent with the microarray and GenMAPP predictions, results from these Western blot experiments demonstrated that transgenic MCF-7 cells overexpressing HMGA1a protein were significantly (2.170.3-fold) more sensitive to 15, 30, and 60 min of EGF activation of the Ras/ERK signaling pathway than were the control parental MCF-7 cells (P ¼ 0.006, 0.013, and 0.009 for 15, 30, and 60 min of EGF treatment, respectively).
Discussion
Induced overexpression of HMGA1 proteins promotes the progression of MCF-7 human breast cancer cells from a state of very low malignancy to a highly aggressive and metastatic phenotype . In this study, oligonucleotide microarray analyses were used to identify genes that were regulated, either directly or indirectly, by the HMGA1a protein in MCF-7 cells overexpressing this protein. These expression array analyses led to the identification, among other things, that the HMGA1a protein regulates sensitivity to the activation of the Ras/ERK signaling pathway ( Figure 5 ). Activated Ras/Raf/MEK/ERK signaling is a major pathway involved in the control of cell growth, survival, and invasion in numerous types of cancer cells and is, therefore, an attractive target for Figure 4 GenMAPP-generated Ras/ERK signaling pathway shaded to correspond with gene expression data. CAV1 ¼ caveolin 1; CAV2 ¼ caveolin 2; ER ¼ estrogen receptor Figure 5 Western blot analysis of phosphorylated ERK-1/2 and total ERK-1/2 protein in parental control (OFF), and HMGA1a-overexpressing (ON) MCF-7 cells, with 0, 15, 30, and 60 min exposure to 30 ng/ml EGF. The intensity for phospho-ERK was determined by densitometry, normalized to total ERK, and reported in arbitrary units. A significant change in phospho-ERK in ON versus OFF cells is indicated with an asterisk and a corresponding P-value above and within each bar, respectively Lee and McCubrey, 2002; Smalley, 2003) .
The Ras/ERK pathway is initiated by extracellular signals that lead to the activation of cytoplasmic signaling molecules containing Src homology 2 (SH2) domains such as Shc. Shc is an SH2-phosphotyrosinebinding domain adaptor protein that links various tyrosine kinases to Ras by recruiting the Grb2/SOS complex to the plasma membrane (Pawson and Scott, 1997 ). SOS activation of Ras then initiates a kinase cascade that culminates in the activation of the mitogenactivated protein kinase ERK (Marshall, 1995) . Activated ERK phosphorylates transcription factors such as Elk-1 and promotes transcription of various target genes leading to the proliferation of the cell.
In this study, we show that overexpression of the HMGA1a isoform upregulates the expression of genes coding for both KITLG and its receptor c-kit. The KITLG/c-kit complex is known to activate the Ras/ ERK cascade through the phosphorylation of Shc (Lennartsson et al., 1999) . We, likewise, demonstrate that caveolins 1 and 2 are downregulated by the overexpression of HMGA1a protein. Caveolin 1 is known to regulate negatively the Ras/ERK pathway (Engelman et al., 1998) and it has been suggested that caveolin 1 may inhibit laminin-induced activation of ERK by sequestering Fyn and Shc in lipid rafts, thereby preventing them from interacting with a-integrins (Fiucci et al., 2002) . Genes encoding enzymes involved in the synthesis of cholesterol, which is an integral part of lipid rafts, were found to be downregulated by HMGA1a (Table 2) . Likewise, insulin-induced gene 1, known to play an important role in regulating the levels of cholesterol within the cell (Janowski, 2002) , was downregulated in HMGA1a-overexpressing cells (Table 1) . Cholesterol depletion of caveolae has been shown to result in the activation of Ras/ERK signaling (Furuchi and Anderson, 1998 ). An enzymatic assay for total cholesterol demonstrated that cholesterol was, as predicted, significantly depleted in HMGA1a-overexpressing cells (Figure 3) . Together, these results indicate that HMGA1 regulates a number of factors that can lead to the activation of Ras/ERK signaling at or near the cell surface.
In addition to regulating expression of genes involved in cell surface initiated events, evidence presented here also indicates that HMGA1 causes subtle changes in the expression of genes coding for proteins that participate in downstream parts of the Ras/ERK signaling pathway. For example, we demonstrate that the expression of Shc is increased by 1.7-fold in cells overexpressing HMGA1a. Other downstream targets of the Ras/ERK pathway are likewise regulated by HMGA1a overexpression including increased expression of Stat-3 and ER, and decreased expression of PPAR-g (Figure 4 ). These results, while subtle, correspond to the expected changes in cells with activated Ras/ERK signaling (Peyssonnaux and Eychene, 2001; Lee and McCubrey, 2002; Smalley, 2003) and are independently supported by the demonstration that MCF-7 cells overexpressing HMGA1a protein are significantly more sensitive to exogenous agents that stimulate the Ras/ERK pathway (such as EGF) leading to the phosphorylation and activation of the ERK protein ( Figure 5 ). Quantitative immunocytochemical experiments employing the anti-phospho-ERK antibody to probe control and HMGA1-overexpressing cells also show a similar HMGA1a-dependent increased EGF sensitivity of the Ras/ERK pathway (data not shown).
The observed HMGA1a-induced changes in the expression of endogenous genes in MCF-7 cells are in agreement with a number of other previously reported findings relating to cancer. For example, it has been demonstrated that artificially induced expression of caveolin 1 in highly malignant MCF-7 cells inhibits their anchorage-independent growth (Fiucci et al., 2002) . Consistent with this finding, here we demonstrate that the overexpression of HMGA1a downregulates the expression of caveolin 1 in MCF-7 cells, while previous studies from this laboratory have shown that such overexpression also induces anchorage-independent growth of MCF-7 cells . Similarly, other researchers have reported that expression of TGFb2, which is downregulated by HMGA1a overexpression (Table 1) , is correlated with phenotypically less malignant human breast cancers that respond better to tamoxifen chemotherapy (Kopp et al., 1995; Brandt et al., 2003) . Likewise, it has been shown that expression of the insulin-induced protein 1 gene is significantly decreased in human gastric cancers (Kaneda et al., 2002) , and here we demonstrate that the expression of this gene is downregulated approximately 2.5-fold in cells overexpressing the HMGA1a protein (Table 1) . Recently, Charpentier et al. (2000) reported that the expression of the estradiol-induced hypothetical protein, E2IG4, is increased in MCF-7 cells following exposure to mitogenic concentrations of estrogen (Charpentier et al., 2000) . Finally, there are reports that increased transcriptional expression of the KITLG gene, shown here to be upregulated by overexpression of HMGA1a (Table 1) , is associated with both density-independent cell growth (Caceres-Cortes et al., 2001) and increased angiogenesis of cancer cells (Zhang et al., 2000) .
In combination with the previous findings , the results reported here strongly suggest that one of the key (but certainly not only) ways that overexpression of HMGA1 proteins promotes tumor progression and increased metastatic potential of human MCF-7 mammary breast cancer cells is through significantly increasing sensitivity to the activation of the Ras/ERK signaling pathway. The HMGA1 genes and proteins may, therefore, represent new chemotherapeutic targets for breast cancer treatment. Most of the present approaches to inhibiting the Ras/ERK pathway in cancerous cells focus on drugs that interfere with the enzymatic activity of various kinases in the signaling cascade. In combination with these existing drug strategies, targeting the activity of the HMGA1 genes or proteins could prove to be a more effective means of cancer treatment than is currently available.
Materials and methods

Cell culture
The MCF-7 cell line (catalog no. HTB-22, ATCC; Manassas, VA, USA) and the hemagglutinin (HA)-tagged HMGA1a-expressing derivative (M/tet/HA-I-Cs) (HMGA1a-ON), stably transfected with the pTRE-HA7C (HMGA1a) expression vector, were maintained as described previously in . Briefly, cells were grown in Dulbecco's modified Eagle's medium (Life Technologies, Inc., Gaithersburg, MD, USA) supplemented with 2 mM L-gutamine, 10 mM HEPES, 10% fetal bovine serum, penicillin G sodium at 100 U/ml, streptomycin sulfate at 100 mg/ml, and hygromycin B at 100 mg/ml, and maintained as recommended by the supplier. For the activation of the Ras/ERK pathway, three replicates of cells were treated for 0, 15, 30, and 60 min with 30 ng/ml murine natural EGF (Invitrogen, Carlsbad, CA, USA).
Northern analysis
Total RNA was isolated from the HMGA1a-expressing, and parental, MCF-7 cells by using TRIzol reagent (Life Technologies, Inc., Gaithersburg, MD, USA) and analysed for quantity and quality using ultraviolet spectrophotometry and agarose-gel electrophoresis, respectively. Total RNA (15 mg) for each sample was electrophoresed on a 1% agarose gel with 5% formaldehyde for 3 h at 100 V. Separated RNA was transferred to a nylon membrane (Micron Separations Inc., Westboro, MA, USA) and incubated with PerfectHyb Plus hybridization buffer (Sigma) for 1 h at 651C. An HMGA1-specific probe was generated by using an HMGA1a restriction fragment from the pTRE-derived (BD Biosciences Clontech, Mountain View, CA, USA) HMGA1a expression vector DNA (pTRE-HA7C; as template for incorporating [a-32 P]dATP with the RadPrime labeling kit (Invitrogen). Approximately, 3 Â 10 8 c.p.m. of probe was incubated with the prehybridized membrane overnight at 651C. The membrane was then washed once with 2 Â SSC and 0.1% sodium dodecyl sulfate (SDS) at room temperature for 10 min, and twice with 0.2 Â SSC and 0.1% SDS at 651C for 10 min. Following overnight exposure to a phosphorimager screen, the hybridization signal was recorded with a Molecular Dynamics PhosphorImager (Amersham Biosciences, Piscataway, NJ, USA).
Western blot analysis
Total protein was prepared from TRIzol extractions by following the manufacturer's protocol. Equal amounts of protein were separated by electrophoresis on an SDS-15% polyacrylamide minigel and transferred to a nitrocellulose membrane (Immobilon-P, Millipore, Bedford, MA, USA) using a semidry electrophoretic transfer cell (Trans-Blot SD; BioRad, Hercules, CA, USA). Immunodetection of the HMGA1 proteins on the membrane was performed using a rabbit polyclonal anti-HMGA1 antibody (MR19), as described in Reeves and Nissen (1999) and a goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (BioRad Laboratories, Hercules, CA, USA). Enhanced chemiluminescence detection (Pierce Biotechnology Inc., Rockford, IL, USA) and hyperfilm MP (Amersham) were used for visualization. Anti-HMGA1 histone H1 crossreactive band of the membrane, along with Coomassie Blue staining of the proteins on SDS-polyacrylamide gels, was used to confirm equal protein loading. Anti-phospho ERK-1/2 (phospho-p44/42 MAPK Thr202/Tyr204) antibody (antibody #9101; Cell Signaling Technology, Beverly, MA, USA) was used along with anti-p44/42 MAPK (ERK-1/2) antibody (antibody #9102), as recommended by the suppliers, to characterize Ras/ERK signaling activation. Molecular Dynamics ImageQuaNT version 4.1b was used to quantify the intensity of phospho-ERK and total ERK bands for each treatment (n ¼ 3). An unpaired Student's t-test was used to calculate the probability that the differences are due to chance (P-value). A P-value less than 0.05 was considered statistically significant.
RT-PCR analysis
Total RNA (1 mg) from TRIzol (Invitrogen) extraction was reverse-transcribed using murine Moloney leukemia virus reverse transcriptase (MMLV-RT (Invitrogen) and oligonucleotide (dT) 12À18 primer (Invitrogen). One-twentieth of the first-strand synthesis reaction was used as template in a PCR with both HMGA1-specific primers (upper, 5 0 -AG ATCTATGAGTGAGT CGAGCTCGAAG-3 0 ; lower-5 0 GG ATCCTGCTGCTCCTCCTCCG-3 0 ) and HPRT1-specific primers (Clontech). Reaction conditions included 1.5 mM MgCl 2 , 200 nM dNTPs, and 0.75 mM of each primer. PCR was set up for 30 cycles of 961C for 30 s, 521C for 45 s, and 721C for 1 min. Amplification was visualized on an ethidium-stained 1% agarose gel.
Microarray analysis
TRIzol (Invitrogen) extracted and RNeasy column (QIAGEN, Valencia, CA, USA) purified total RNA (10 mg) was used to synthesize the microarray target. Target synthesized from RNA from three independent parental and HMGA1a-expressing MCF-7 cell preparations was hybridized to the microarrays. RNA was reverse transcribed to generate double-stranded cDNA with a T7 promoter-containing primer using Superscript II, RNase H, and DNA polymerase (Invitrogen). After extraction with phenol-chloroform and ethanol precipitation with ammonium acetate, the cDNA was used as template in an in vitro transcription reaction with biotin-labeled RNA (MEGAscript T7, High Yield Translation kit, Ambion, Austin, TX, USA). Resulting target cRNA was collected on RNeasy columns (QIAGEN) and then fragmented for hybridization to the microarrays. Affymetrix human genome U133A gene chip arrays were used to analyse gene expression (Affymetrix Inc., Santa Clara, CA, USA). This array consists of approximately 22 000 genes from Homo sapiens. Probes consist of 11 pairs of 25-mer oligonucleotides for each gene. One member of each pair contains a single base point mutation, and the signals of the pairs are compared to assess specificity of hybridization. Biotinylated target cRNA (15 mg) was hybridized to the array and then processed using the Affymetrix GeneChip Fluidics Workstation 400, using the Mini Euk 2v3 protocol. After binding with phycoerythrincoupled avidin, microarrays were scanned on an Agilent Technologies Gene Array Scanner (Agilent Technologies, Palo Alto, CA, USA). Results were analysed using Affymetrix Microarray Software (MAS) 5.0. Individual microarrays were scaled to produce a mean signal intensity of 125. Iterative comparisons of different microarray data sets were performed with MAS 5.0 comparison analysis as described previously with the modifications in Chen et al. (2000) . Three replicate HMGA1a-expressing MCF-7 cell microarray data sets were compared with each of the three replicate parental MCF-7 cell (control) microarray data sets to determine the expression difference between HMGA1a and control. This comparison strategy allowed statistical comparison of fold-change values (converted from signal log ratio obtained from MAS 5.0) for genes that survived the three pairwise comparisons with a fold change X2. For analysis with the Gene MicroArray Pathway Profiler (GenMAPP, Version 1.0; Gladstone Institutes, University of California, SF, USA; www.GenMAPP.org), the average fold-change values for each gene on the microarray, along with the Swiss-Prot database ID supplied by Affymetrix, were uploaded as a comma separated value-formatted file. An average fold change of greater than or equal to 1.5 was used as the criteria for whether a specific gene was up-or downregulated by HMGA1.
Quantitative real-time RT-PCR analysis Q-PCR was performed using Assays-on-Demand and an ABI PRISM s 7000 Sequence Detection System on human target genes, caveolin 1, caveolin 2, and c-kit ligand, and an endogenous control, HPRT1 (assay IDs Hs00184697_m1, Hs00184597_m1, Hs00241497_m1, and Hs99999909_m1, respectively; Applied Biosystems, Foster City, CA, USA). TRIzol (1 mg) extracted total RNA was reverse transcribed using 20 mM oligonucleotide (dT) 12À18 , and 1 U MMLV-RT (Invitrogen). One-twentieth of the RT reaction (50 ng of RNA converted to cDNA) was used as template for the PCR step using TaqMan Universal PCR Master Mix, No AmpErase UNG, as recommended by the supplier (Applied Biosystems). Q-PCR was performed using Assays-on Demand and TaqMan 5 0 fluorogenic nuclease chemistry (Applied Biosystems). Each assay consists of two unlabeled PCR primers, and an FAM dye-labeled TaqMan minor groove binder (MGB) probe. During PCR, the TaqMan MGB probe anneals specifically to cDNA between the forward and reverse primer sites. When the probe is intact, the proximity of the reporter dye to the quencher dye results in the suppression of the reporter fluorescence. AmpliTaq Gold DNA polymerase cleaves only probes that are hybridized to the target. Cleavage separates the reporter dye from the quencher dye, which results in increased fluorescence by the reporter. The increase in fluorescence signal occurs only if the target sequence is complementary to the probe and is amplified during PCR. Fluorescence is detected at each cycle using an ABI PRISM s 7000 Sequence Detection System (Applied Biosystems). Relative quantitation was carried out using the comparative cycle threshold (C T ) method as recommended by the supplier.
Cholesterol assay
Isolation of total cholesterol was carried out following Heider and Boyett (1978) . Approximately, 1 Â 10 6 parental and HMGA1a-overexpressing MCF-7 cells were washed in phosphate-buffered saline and spun at 1000 r.p.m. for 10 min. The pellet was resuspended in 1 ml isopropanol and sonicated for 15 s at 35% output (Fisher sonic dismembrator model 300) to extract cholesterol and cholesterol esters. The sonicated suspension was spun at 12 000 g for 15 min. Supernatant (100 ml) was added to 700 ml Infinity Cholesterol Reagent (Sigma Diagnostics, St Louis, MO, USA) for 15 min at B241C before recording the absorbance at 510 nm. A standard curve was generated by diluting 50 ml of 100, 200, and 400 mg/dl cholesterol standards into 950 ml of isopropanol. A measure of 100 ml of each solution, along with isopropanol alone (used for background correction), were added, in parallel, to 700 ml Infinity Cholesterol Reagent for 15 min at B241C before recording the absorbance at 510 nm. For each experimental sample, total cholesterol was normalized to total protein from the isopropanol pellet as determined by absorbance at 280 nm and a standard curve with bovine serum albumin.
